Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger
Mylan (NASDAQ: MYL) delivered disappointing results across the board in April when the drugmaker provided its first-quarter update. Investors were left wondering what Mylan might do to turn things around. They now have an answer.
On Monday, Mylan and Pfizer announced plans to combine Pfizer's Upjohn unit with Mylan in an all-stock transaction. Pfizer's shareholders will own 57% of the combined company, with Mylan's shareholders owning 43%.
This big story overshadowed Mylan's other news: The drugmaker reported its second-quarter results before the market opened on Monday. Here's what you need to know about how Mylan performed in the second quarter.
Quelle Fool.com
